Signaling Leadership Confidence and Commitment to Company Forthcoming 10-K Filing and Earnings Call Scheduled for September 29–30, 2025, respectively TAMPA, Fla., September 24th, 2025 — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear Holdings” or the “Company”) today announced the successful closing of the remaining $2,000,000 of the previously announced $5… Read More..

The ALSTARS Trial is a well powered randomized, multi-center, double-blind, placebo-controlled, 24-week study of COYA 302 in people with Amyotrophic Lateral Sclerosis (ALS) Patients completing the initial 24-week treatment will be invited to participate in a 24-week blinded extension period, during which all participants will receive COYA 302 The ALSTARS… Read More..

TAMPA, Fla., September 17, 2025--(BUSINESS WIRE)--AtlasClear Holdings, Inc. (NYSE American: ATCH) announces closing of $3,000,000 financing. AtlasClear Holdings, Inc. ("AtlasClear Holdings" or the "Company") reported today it raised $3,000,000 in gross proceeds through the issuance of promissory notes from strategic investors. The Company may raise up to an additional $2,000,000… Read More..